138 related articles for article (PubMed ID: 26508157)
1. Detecting tau in serum of transgenic animal models after tau immunotherapy treatment.
d'Abramo C; Acker CM; Schachter JB; Terracina G; Wang X; Forest SK; Davies P
Neurobiol Aging; 2016 Jan; 37():58-65. PubMed ID: 26508157
[TBL] [Abstract][Full Text] [Related]
2. Tau-targeting passive immunization modulates aspects of pathology in tau transgenic mice.
Ittner A; Bertz J; Suh LS; Stevens CH; Götz J; Ittner LM
J Neurochem; 2015 Jan; 132(1):135-45. PubMed ID: 25041093
[TBL] [Abstract][Full Text] [Related]
3. Passive Immunization in JNPL3 Transgenic Mice Using an Array of Phospho-Tau Specific Antibodies.
d'Abramo C; Acker CM; Jimenez H; Davies P
PLoS One; 2015; 10(8):e0135774. PubMed ID: 26270821
[TBL] [Abstract][Full Text] [Related]
4. Anti-tau conformational scFv MC1 antibody efficiently reduces pathological tau species in adult JNPL3 mice.
Vitale F; Giliberto L; Ruiz S; Steslow K; Marambaud P; d'Abramo C
Acta Neuropathol Commun; 2018 Aug; 6(1):82. PubMed ID: 30134961
[TBL] [Abstract][Full Text] [Related]
5. Tau immunotherapy for Alzheimer's disease.
Pedersen JT; Sigurdsson EM
Trends Mol Med; 2015 Jun; 21(6):394-402. PubMed ID: 25846560
[TBL] [Abstract][Full Text] [Related]
6. Tau antibody isotype induces differential effects following passive immunisation of tau transgenic mice.
Bajracharya R; Brici D; Bodea LG; Janowicz PW; Götz J; Nisbet RM
Acta Neuropathol Commun; 2021 Mar; 9(1):42. PubMed ID: 33712083
[TBL] [Abstract][Full Text] [Related]
7. Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression.
Chai X; Wu S; Murray TK; Kinley R; Cella CV; Sims H; Buckner N; Hanmer J; Davies P; O'Neill MJ; Hutton ML; Citron M
J Biol Chem; 2011 Sep; 286(39):34457-67. PubMed ID: 21841002
[TBL] [Abstract][Full Text] [Related]
8. Specific targeting of tau oligomers in Htau mice prevents cognitive impairment and tau toxicity following injection with brain-derived tau oligomeric seeds.
Castillo-Carranza DL; Gerson JE; Sengupta U; Guerrero-Muñoz MJ; Lasagna-Reeves CA; Kayed R
J Alzheimers Dis; 2014; 40 Suppl 1():S97-S111. PubMed ID: 24603946
[TBL] [Abstract][Full Text] [Related]
9. Combined effects of scanning ultrasound and a tau-specific single chain antibody in a tau transgenic mouse model.
Nisbet RM; Van der Jeugd A; Leinenga G; Evans HT; Janowicz PW; Götz J
Brain; 2017 May; 140(5):1220-1230. PubMed ID: 28379300
[TBL] [Abstract][Full Text] [Related]
10. Oligomeric tau-targeted immunotherapy in Tg4510 mice.
Schroeder S; Joly-Amado A; Soliman A; Sengupta U; Kayed R; Gordon MN; Morgan D
Alzheimers Res Ther; 2017 Jun; 9(1):46. PubMed ID: 28655349
[TBL] [Abstract][Full Text] [Related]
11. Novel Phospho-Tau Monoclonal Antibody Generated Using a Liposomal Vaccine, with Enhanced Recognition of a Conformational Tauopathy Epitope.
Theunis C; Adolfsson O; Crespo-Biel N; Piorkowska K; Pihlgren M; Hickman DT; Gafner V; Borghgraef P; Devijver H; Pfeifer A; Van Leuven F; Muhs A
J Alzheimers Dis; 2017; 56(2):585-599. PubMed ID: 28035925
[TBL] [Abstract][Full Text] [Related]
12. Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain.
Boutajangout A; Ingadottir J; Davies P; Sigurdsson EM
J Neurochem; 2011 Aug; 118(4):658-67. PubMed ID: 21644996
[TBL] [Abstract][Full Text] [Related]
13. Epitope analysis following active immunization with tau proteins reveals immunogens implicated in tau pathogenesis.
Selenica ML; Davtyan H; Housley SB; Blair LJ; Gillies A; Nordhues BA; Zhang B; Liu J; Gestwicki JE; Lee DC; Gordon MN; Morgan D; Dickey CA
J Neuroinflammation; 2014 Sep; 11():152. PubMed ID: 25183004
[TBL] [Abstract][Full Text] [Related]
14. [Passive Tau immunotherapy for prevention of Tau pathology progression].
Ozmen L; Collin L
Med Sci (Paris); 2015 Feb; 31(2):132-4. PubMed ID: 25744257
[No Abstract] [Full Text] [Related]
15. Tau Immunotherapy.
Sigurdsson EM
Neurodegener Dis; 2016; 16(1-2):34-8. PubMed ID: 26551002
[TBL] [Abstract][Full Text] [Related]
16. Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity.
d'Abramo C; Acker CM; Jimenez HT; Davies P
PLoS One; 2013; 8(4):e62402. PubMed ID: 23638068
[TBL] [Abstract][Full Text] [Related]
17. Passive Immunotherapy Targeting Tau Oligomeric Strains Reverses Tauopathy Phenotypes in Aged Human-Tau Mice in a Mouse Model-Specific Manner.
Bittar A; Al-Lahham R; Bhatt N; Moore K; Montalbano M; Jerez C; Fung L; McAllen S; Ellsworth A; Kayed R
J Alzheimers Dis; 2022; 90(3):1103-1122. PubMed ID: 36189593
[TBL] [Abstract][Full Text] [Related]
18. Tau-Directed Immunotherapy: A Promising Strategy for Treating Alzheimer's Disease and Other Tauopathies.
Schroeder SK; Joly-Amado A; Gordon MN; Morgan D
J Neuroimmune Pharmacol; 2016 Mar; 11(1):9-25. PubMed ID: 26538351
[TBL] [Abstract][Full Text] [Related]
19. Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy.
Yanamandra K; Patel TK; Jiang H; Schindler S; Ulrich JD; Boxer AL; Miller BL; Kerwin DR; Gallardo G; Stewart F; Finn MB; Cairns NJ; Verghese PB; Fogelman I; West T; Braunstein J; Robinson G; Keyser J; Roh J; Knapik SS; Hu Y; Holtzman DM
Sci Transl Med; 2017 Apr; 9(386):. PubMed ID: 28424326
[TBL] [Abstract][Full Text] [Related]
20. Repeated immunization of mice with phosphorylated-tau peptides causes neuroinflammation.
Rozenstein-Tsalkovich L; Grigoriadis N; Lourbopoulos A; Nousiopoulou E; Kassis I; Abramsky O; Karussis D; Rosenmann H
Exp Neurol; 2013 Oct; 248():451-6. PubMed ID: 23876516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]